

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Marsha A. Moses, Li Yan

09/977,878

Group No.: 1642

Filed:

10/15/01 Examiner: Karen A. Canella

For:

NON-INVASIVE ENZYME SCREEN FOR TISSUE REMODELLING

ASSOCIATED CONDITIONS

CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the united States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Nicole M. Gignac

(type or print name of person mailing paper)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir/Madam:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §1.56, 1.97, and 1.98, Applicants wish to bring to the Examiner's attention the following references, References AA, BA, and CA - CI, cited in the attached Form PTO-1449.

01/28/2004 HGUTEMA1 00000097 09977878

01 FC:1806

180.00 GP

Marsha A. Moses, Li Yan

09/977,878 10/15/01

Group No.: 1642

Examiner: Karen A. Canella

NON-INVASIVE ENZYME SCREEN FOR TISSUE REMODELLING ASSOCIATED CONDITIONS

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

- (1) within three (3) months of the Filing Date or **before the mailing date of the First**Office Action on the merits; or
 - (2) within three months of the mailing date of the PCT International Search Report; or
- X after the period defined in (1) but before the mailing date of a Final Rejection or Notice of Allowance, and the requisite Certification or fee under Rule 1.17(p), namely \$180.00, is included herein; or
 - (4) after the mailing date of a **Final Rejection** or **Notice of Allowance** but before the payment of the **Issue Fee**, and the requisite Certification, petition, and petition fee are included herein.
- X A copy of the International Search Report is enclosed herewith.

It is respectfully requested that each of the documents shown on the attached form(s) PTO-1449 be made of record in this application.

Copies of these documents (CHECK ONE):

X are enclosed herewith; orhave been cited in the parent application, and are thus not being resubmitted herein.

FEE AUTHORIZATION

The Commissioner is authorized to charge fee deficiencies or credit overpayments associated with this submission to the NIXON PEABODY LLP Deposit Account No. 50-0850.

Date:

Respectfully submitted,

Bavid S. Resnick (Reg. No. 34,235)

NIXON PEABODY LLP

101 Federal Street Boston, MA 02110

(617) 345-6057

PTO/SB/17 (10-03)

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE work Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE	TR	RAN	SMI	ı, b	AL
PACELLA	for	FY	200	4	

Effective 10/01/2003. Patent fees are subject to annual revision.

X Applicant claims small entity status. See 37 CFR 1.27

180.00 TOTAL AMOUNT OF PAYMENT (\$)

BATTER

Name (Print/Type)

Signature

David S. Resnick

Complete if Known				
Application Number	09/997,878			
Filing Date	10/15/2001	-		
First Named Inventor	M.A. Moses			
Examiner Name	K.A. Canella			
Art Unit	1642			
Attorney Docket No.	701039-054701			

METHOD OF PAYMENT (check all that apply)	1	FEE CALCULATION (continued)				
X Check Credit card Money Other None 3. ADDITIONAL FEES						
Large Entity , Small Entity						
X Deposit Account: Deposit	Fee	Fee	Fee	Fee	Fee Description	
Account 50-0850	Code	• • •	Code	***		Fee Paid
Number Deposit	1051	130	2051		Surcharge - late filing fee or oath	ļ
Account NIXON PEABODY LLP	1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	<u> </u>
Name Land I have been sufficient to the control of	1053	130	1053	130	Non-English specification	<u> </u>
Charge fee(s) indicated below Credit any overpayments	1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
X Charge any additional fee(s) or any underpayment of fee(s)	1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
Charge fee(s) indicated below, except for the filing fee	1805	1,840*	1805	1,840*	Requesting publication of SIR after	
to the above-identified deposit account.			l		Examiner action	
FEE CALCULATION	1251	110	2251		Extension for reply within first month	
1. BASIC FILING FEE	1252	420	2252		• •	
Large Entity Small Entity Fee Fee Fee Fee Description Fee Paid	1253	950	2253		Extension for reply within third month	
Code (\$) Code (\$)	1254	1,480	2254		Extension for reply within fourth month	l
1001 770 2001 385 Utility filing fee	1255	2,010	2255	1,005	Extension for reply within fifth month	
1002 340 2002 170 Design filing fee	1401	330	2401	165	Notice of Appeal	
1003 530 2003 265 Plant filing fee	1402	330	2402	165	Filing brief in support of an appeal	
1004 770 2004 385 Reissue filing fee	1403	290	2403	145	Request for oral hearing	
1005 160 2005 80 Provisional filing fee	1451	1,510	1451	1,510	Petition to institute a public use proceeding	
SUBTOTAL (1) (\$)	1452	110	2452	55	Petition to revive - unavoidable	<u> </u>
		1,330	2453	665	Petition to revive - unintentional	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUI	1501	1,330	2501	665	Utility issue fee (or reissue)	
Extra Claims below Fee Paid	1502	480	2502	240	Design issue fee	
Independent	1503	640	2503		Plant issue fee	
Claims 3** = X = X = Multiple Dependent	1460	130	1460	130	Petitions to the Commissioner	
· ·	J 1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
Large Entity Small Entity Fee Fee Fee Fee Fee Description	1806	180	1806	180	Submission of Information Disclosure Stmt	180.00
Code (\$) Code (\$)	8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1202 18 2202 9 Claims in excess of 20	1809	770	2809	385	Filing a submission after final rejection	
1201 86 2201 43 Independent claims in excess of 3 1203 290 2203 145 Multiple dependent claim, if not paid	4040	770		005	(37 CFR 1.129(a))	<u> </u>
1204 86 2204 43 ** Reissue independent claims	1810	770	2810	385	For each additional invention to be examined (37 CFR 1.129(b))	
over original patent	1801	770	2801	385	Request for Continued Examination (RCE)	
1205 18 2205 9 ** Reissue claims in excess of 20	1802	900	1802	900	Request for expedited examination	
and over original patent of a design application Other fee (specify)						
SUBTOTAL (2) (\$)	I B			Filing F	Fee Paid SURTOTAL (3) (\$)	180.00
**or number previously paid, if greater, For Reissues, see above	1				ee Paid SUBTOTAL (3) (\$)	180.00
SUBMITTED BY	ATTEMPORAL MENTAL INC.				(Complete (if applicable)	
Name (Print/Type) Dovid S @ oppiols Registration No. 24 225 Telephone (CLT) 245 (057)						

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

(Attorney/Agent)

34,235

Telephone

Date

(617)/345-6057

JAN 2 6 2004 LU Substitute for form Land PTO

Sheet

1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

2

Complete if Known			
Application Number	09/977,878		
Filing Date	10/15/2001		
First Named Inventor	Marsha A. Moses		
Art Unit	1642		
Examiner Name	Karen A. Canella		
Attorney Docket Number	701039-054701		

	U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	U.S. Patent Document Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	AA	US-6,037,138	03-14-2000	Moses et al.			
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
	 _	US-					
		US-					
	1	US-					

		FC	REIGN PATENT	DOCUMENTS		
Examiner Cite Initials No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Cohumns, Lines, Where Relevant Passages or Relevant Figures Appear		
	Country Code ³ Number ⁴ (if known)				T ⁶	
	BA	WO 97/41441 A2, A3	11-06-1997	Children's Medical Center Corporation		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

Examiner

Signature

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222 uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

JAN 2 6 2008 W Substitute for form 449A/PTO PACE BANK TION

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known			
Application Number	09/977,878		
Filing Date	10/15/2001		
First Named Inventor	Marsha A. Moses		
Art Unit	1642		
Examiner Name	Karen A. Canella		
Attorney Docket Number	701039-054701		

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	.,
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Baker, T. et al. "Serum metalloproteinases and their inhibitors: markers for malignant potential." Br J Cancer. 1994 Sep.; 70(3):506-12.	
	СВ	Garbisa, S. et al. "Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy." Cancer Res. 1992 Aug 15; 52(16):4548-9.	
	CC	Kleiner, D.E. et al. "Matrix metalloproteinases and metastasis." Cancer Chemother. Pharmacol. 1999; 43 Suppl:S42-51.	
	CD	Lochter, A. et al. "The significance of matrix metalloproteinases during early stages of tumor progression." Ann N Y Acad Sci. 1998 Oct 23; 857:180-93.	
	CE	Monier, F. et al. "Gelatinase isoforms in urine from bladder cancer patients" Clin. Chim. Acta. 2000 Sep; 299 (1-2):11-23.	-
	CF	Moses, M. et al. "Increased incidence of matrix metalloproteinases in urine of cancer patients" Cancer Res. 1998 Apr 1; 58(7): 1395-9.	
	CG	Nakajima, M. et al. "Serum and plasma M(r) 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762 NF mammary adenocarcinoma." Cancer Res. 1993 Dec 1; 53(23):5802-7.	
	СН	Yan, <i>Li, et a1</i> . "The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL" <i>J Biol Chem.</i> 2001 Oct 5;276(40):37258-65.	
	CI	Zucker, S. et al. "Plasma assay of matrix metalloproteinases (MMPs) and MMP inhibitor complexes in cancer. Potential use in predicting metastasis and monitoring treatment." Ann NY Acad. Sci. 1994 Sep 6; 732:248-62.	

		
Examiner	Date	
Signature	 Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number **Application Number** 09/977,878 TRANSMITTAL Filing Date 10/15/2001 FORM First Named Inventor M.A. Moses Art Unit all correspondence after initial filing) 1642 **Examiner Name** K.A. Canella PADE A Number of Pages in This Submission Attorney Docket Number 701039-054701 **ENCLOSURES** (Check all that apply) After Allowance Communication Fee Transmittal Form Drawing(s) to Group Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to Group Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Proprietary Information After Final **Provisional Application** Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Terminal Disclaimer Extension of Time Request Identify below): Form 1449; References AA, BA and CA - CI; Certificate of Request for Refund **Express Abandonment Request** Mailing; Return Receipt Postcard. CD, Number of CD(s) Information Disclosure Statement Remarks Certified Copy of Priority Document(s) The Commissioner is authorized to charge deficiencies associated with this submission Response to Missing Parts/ to the NIXON PEABODY LLP Deposit Account No. 50-0850. Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm David S. Resnick (Reg. No. 34,235) NIXON PEABODY LLP, 101 Federal Street, Boston, MA 02110 Individual name Signature Date CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. Washington, DC 20231 on this date: Typed or printed name Nicole M. Gignac Signature Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Image

Attorney Docket No. 701039-054701

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Marsha A. Moses, Li Yan

Application No.:

09/977,878

Group No.: 1642

Filed:

10/15/01 Examiner: Karen A. Canella

For:

NON-INVASIVE ENZYME SCREEN FOR TISSUE REMODELLING

ASSOCIATED CONDITIONS

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. § 1.8(a) and 1.10)

I hereby certify that this correspondence:

1. Transmittal Form (1 pg.);

- 2. Information Disclosure Statement (2 pp.);
- 3. Form 1449 (2 pp.);
- 4. References AA, BA, and CA CI;
- 5. Fee Transmittal (1 pg.);
- 6. Check \$180.00;
- 7. Return Receipt Postcard;

is on the date shown below being:

MAILING

X deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22202

Date:

FACSIMILE

transmitted by facsimile to the Patent and Trademark Office.

Signature

Nicole M. Gignac

(type or print name of person certifying)